Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Regulation of prefrontal cortex myelination by the microbiota.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Dilantin
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Power estimation for non-standardized multisite studies.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Intas launches biosimilar version of Rituximab
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.

Pages